Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition

Publisher： Elsevier

ISSN： 0015-0282

Source： Fertility and Sterility, Vol.75, Iss.5, 2001-05, pp. : 865-870

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The combined contraceptive vaginal device (NuvaRing®): A comprehensive review

By Sarkar NN

The European Journal of Contraception and Reproductive Health Care, Vol. 10, Iss. 2, 2005-06 ,pp. : 73-78

Informa Healthcare

Access to resources Recommend Favorite

The combined contraceptive vaginal ring (NuvaRing®): First experience in daily clinical practice in The Netherlands

By Roumen Frans Berg Monique M. T. op ten Hoomans Eric

The European Journal of Contraception and Reproductive Health Care, Vol. 11, Iss. 1, 2006-03 ,pp. : 14-22

Informa Healthcare

Access to resources Recommend Favorite

The contraceptive vaginal ring, NuvaRing^®, a decade after its introduction

By Roumen Frans J. M. E. Mishell Daniel R.

The European Journal of Contraception and Reproductive Health Care, Vol. 17, Iss. 6, 2012-12 ,pp. : 415-427

Informa Healthcare

Access to resources Recommend Favorite

A comparative study on the effects of a contraceptive vaginal ring NuvaRing^® and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function

By Duijkers I Killick S Bigrigg A Dieben Tom

The European Journal of Contraception and Reproductive Health Care, Vol. 9, Iss. 3, 2004-09 ,pp. : 131-140

Informa Healthcare

Access to resources Recommend Favorite

The contraceptive vaginal ring, NuvaRing(R), and antimycotic co-medication

By Verhoeven C.H.J. van den Heuvel M.W. Mulders T.M.T. Dieben T.O.M.

Contraception, Vol. 69, Iss. 2, 2004-02 ,pp. : 129-132

Elsevier

Access to resources Recommend Favorite